Search

Your search keyword '"Licitra, L"' showing total 1,119 results
Start Over Author "Licitra, L"
1,119 results on '"Licitra, L"'

151. Prognostic Value of Metabolic Parameters by 18 F-FDG PET/CT in Nasopharyngeal Cancer (NPC) in Non-Endemic Area

Author

Cavallo, A., primary, Cicchetti, A., additional, Iacovelli, N.A., additional, Alessi, A., additional, Padovano, B., additional, Colombo, C., additional, Facchinetti, N., additional, Alfieri, S., additional, Bossi, P., additional, Resteghini, C., additional, Licitra, L., additional, Fallai, C., additional, Crippa, F., additional, Rancati, T., additional, Pignoli, E., additional, and Orlandi, E., additional

Published
2017
Full Text
View/download PDF

153. Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma

Author

Alfieri, S., primary, Bossi, P., additional, Galbiati, D., additional, Giannoccaro, M., additional, Pilotti, S., additional, Perrone, F., additional, Paielli, N., additional, Tonella, L., additional, Bergamini, C., additional, Granata, R., additional, Resteghini, C., additional, Cavalieri, S., additional, Iacovelli, N.A., additional, Orlandi, E., additional, Locati, L.D., additional, Licitra, L., additional, Canevari, S., additional, and De Cecco, L., additional

Published
2017
Full Text
View/download PDF

154. Association Between Toxicity Profiles During Radiation Therapy (RT) for Oropharyngeal Cancer and CBCT-Derived and Dosimetric Factors to Evaluate Global Toxicity During RT for Oropharyngeal Cancer

Author

Facchinetti, N., primary, Cavallo, A., additional, Cicchetti, A., additional, Iacovelli, N.A., additional, Frasca, S., additional, Naimo, S., additional, Alfieri, S., additional, Bergamini, C., additional, Locati, L., additional, Licitra, L., additional, Fallai, C., additional, Pignoli, E., additional, and Orlandi, E., additional

Published
2017
Full Text
View/download PDF

155. A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma

Author

Bossi, P., primary, Cavalieri, S., additional, Perrone, F., additional, Miceli, R., additional, Ascierto, P., additional, Locati, L., additional, Bergamini, C., additional, Granata, R., additional, Alfieri, S., additional, Resteghini, C., additional, Galbiati, D., additional, Busico, A., additional, Paielli, N., additional, Patuzzo, R., additional, Maurichi, A., additional, Gallino, G., additional, Ruggeri, R., additional, Mariani, L., additional, Palla, M., additional, and Licitra, L., additional

Published
2017
Full Text
View/download PDF

156. Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer

Author

Granata, R., primary, Orlandi, E., additional, Infante, G., additional, Iacovelli, N.A., additional, Miceli, R., additional, Cavallo, A., additional, Alfieri, S., additional, Bergamini, C., additional, Resteghini, C., additional, Galbiati, D., additional, Cavalieri, S., additional, Locati, L., additional, Tana, S., additional, Naimo, S., additional, Fallai, C., additional, Licitra, L., additional, and Bossi, P., additional

Published
2017
Full Text
View/download PDF

157. A single institution twenty-year experience of recurrent or metastatic epithelial non glandular sinonasal cancer

Author

Cavalieri, S., primary, Granata, R., additional, Locati, L., additional, Bergamini, C., additional, Alfieri, S., additional, Resteghini, C., additional, Galbiati, D., additional, Orlandi, E., additional, Iacovelli, N.A., additional, Calareso, G., additional, Guzzo, M., additional, Quattrone, P., additional, Licitra, L., additional, and Bossi, P., additional

Published
2017
Full Text
View/download PDF

158. First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial

Author

Bossi, P., primary, Hollander, L.H., additional, Miceli, R., additional, Ferrari, D., additional, Vecchio, S., additional, Moretti, G., additional, Merlano, M., additional, Caponigro, F., additional, Moro, C., additional, Vaccher, E., additional, Alabisio, O., additional, Caldara, A., additional, Russo, A., additional, Ferrau, F., additional, Nolè, F., additional, and Licitra, L., additional

Published
2017
Full Text
View/download PDF

159. Sinonasal non-glandular cancers relapsing after multimodal treatments

Author

Cavalieri, S., primary, Granata, R., additional, Locati, L.D., additional, Bergamini, C., additional, Alfieri, S., additional, Resteghini, C., additional, Galbiati, D., additional, Orlandi, E., additional, Iacovelli, N.A., additional, Calareso, G., additional, Guzzo, M., additional, Quattrone, P., additional, Licitra, L., additional, and Bossi, P., additional

Published
2017
Full Text
View/download PDF

160. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Author

Cohen, E.E., primary, Harrington, K.J., additional, Le Tourneau, C., additional, Dinis, J., additional, Licitra, L., additional, Ahn, M-J., additional, Soria, A., additional, Machiels, J-P., additional, Mach, N., additional, Mehra, R., additional, Burtness, B., additional, Wang, Y., additional, Tuozzo, A.J., additional, Swaby, R., additional, and Soulieres, D., additional

Published
2017
Full Text
View/download PDF

161. Nivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141

Author

Licitra, L., primary, Ferris, R.L., additional, Blumenschein, G., additional, Harrington, K.J., additional, Guigay, J., additional, Kasper, S., additional, Saba, N.F., additional, Haddad, R., additional, Kiyota, N., additional, Monga, M., additional, Lynch, M., additional, Li, L., additional, Gillison, M.L., additional, and Fayette, J., additional

Published
2017
Full Text
View/download PDF

162. Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC

Author

Locati, L.D., primary, Caballero, C., additional, Fortpied, C., additional, Perrone, F., additional, Pilotti, S., additional, Harrington, K.J., additional, Grégoire, V., additional, and Licitra, L., additional

Published
2017
Full Text
View/download PDF

163. Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma

Author

Boxtel, W., primary, Locati, L.D., additional, Tooten, S., additional, Bos, E., additional, Bergamini, C., additional, van Engen-van Grunsven, A.C.H., additional, Boon, E., additional, Fiets, E., additional, Cavalieri, S., additional, Verhaegh, G., additional, Schalken, J., additional, Licitra, L., additional, and Herpen, C.M.L., additional

Published
2017
Full Text
View/download PDF

165. Long-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Analysis of the LUX-Head & Neck 1 (LHN1) trial

Author

Machiels, J-P., primary, de Castro, G., additional, de Souza Viana, L., additional, Galiulin, R., additional, Tahara, M., additional, Nicolau, U.R., additional, Le Tourneau, C., additional, Okami, K., additional, Vladimirov, V., additional, Izmailov, A., additional, Hoermann, K., additional, Licitra, L., additional, Haddad, R., additional, Cohen, E., additional, Dupuis, N., additional, Love, J., additional, Zografos, E., additional, Ehrnrooth, E., additional, and Fayette, J., additional

Published
2017
Full Text
View/download PDF

167. Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes

Author

Haddad, R., primary, Blumenschein, G., additional, Fayette, J., additional, Guigay, J., additional, Colevas, A.D., additional, Licitra, L., additional, Kasper, S., additional, Vokes, E.E., additional, Worden, F., additional, Saba, N.F., additional, Tahara, M., additional, Concha-Benavente, F., additional, Monga, M., additional, Lynch, M., additional, Li, L., additional, Shaw, J.W., additional, Gillison, M.L., additional, Harrington, K.J., additional, and Ferris, R.L., additional

Published
2017
Full Text
View/download PDF

168. Natural history and prognostic factors of head and neck cancer patients with bone metastases: A retrospective Italian study

Author

Grisanti, S., primary, Bergamini, C., additional, Bianchi, S., additional, Baiguini, A., additional, Vecchio, S., additional, Locati, L.D., additional, Bonetta, A., additional, Conte, P.F., additional, Airoldi, M., additional, Merlano, M., additional, Carlini, P., additional, Ibrahim, T., additional, Rossetto, C., additional, Nicolai, P., additional, Maroldi, R., additional, Tonoli, S., additional, Pronzato, P., additional, Magrini, S.M., additional, Licitra, L., additional, and Berruti, A., additional

Published
2017
Full Text
View/download PDF

169. OC-021: Biomarker results from BERIL-1: buparlisib and paclitaxel in patients with platinum-pretreated SCCHN

Author

Soulières, D., primary, Faivre, S., additional, Mesía, R., additional, Remenár, E., additional, Li, S.H., additional, Karpenko, A., additional, Dechaphunkul, A., additional, Keilholz, U., additional, Kiss, L., additional, Lin, J.C., additional, Nagarkar, R., additional, Tamás, L., additional, Kim, S.B., additional, Erfán, J., additional, Alyasova, A., additional, Yovine, A., additional, Le Mouhaër, S., additional, Solovieff, N., additional, Turri, S., additional, and Licitra, L., additional

Published
2017
Full Text
View/download PDF

170. PD-034: Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer

Author

Orlandi, E., primary, Infante, G., additional, Granata, R., additional, Iacovelli, N., additional, Miceli, R., additional, Cavallo, A., additional, Alfieri, S., additional, Bergamini, C., additional, Resteghini, C., additional, Galbiati, D., additional, Locati, L., additional, Tana, S., additional, Naimo, S., additional, Fallai, C., additional, Licitra, L., additional, and Bossi, P., additional

Published
2017
Full Text
View/download PDF

171. OC-019: The phase III study INTERCEPTOR: preliminary results

Author

Denaro, N., primary, Vecchio, S., additional, Bagicalupo, A., additional, Russi, E., additional, Rampino, M., additional, Benasso, M., additional, Numico, G., additional, Licitra, L., additional, Ostellino, O., additional, D'amico, M., additional, Curcio, P., additional, and Merlano, M., additional

Published
2017
Full Text
View/download PDF

172. Dissecting heterogeneity and molecular mechanisms involved in paranasal sinus cancer

Author

De Cecco, L., primary, Granata, R., additional, Orlandi, E., additional, Fallai, C., additional, Licitra, L., additional, Giannoccaro, M., additional, Perrone, F., additional, Pilotti, S., additional, Quattrone, P., additional, Facco, C., additional, Sessa, F., additional, Turri-Zanoni, M., additional, Battaglia, P., additional, Castelnuovo, P., additional, Antognoni, P., additional, Paielli, N., additional, Tonella, L., additional, Canevari, S., additional, and Bossi, P., additional

Published
2016
Full Text
View/download PDF

174. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies

Author

Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, CIARDIELLO, Fortunato, Licitra, L, Störkel, S, Kerr, Km, Van Cutsem, E, Pirker, R, Hirsch, Fr, Vermorken, Jb, von Heydebreck, A, Esser, R, Celik, I, and Ciardiello, Fortunato

Published
2013

175. Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III

Author

Singer, S. Araújo, C. Arraras, J.I. Baumann, I. Boehm, A. Brokstad Herlofson, B. Castro Silva, J. Chie, W.-C. Fisher, S. Guntinas-Lichius, O. Hammerlid, E. Irarrázaval, M.E. Jensen Hjermstad, M. Jensen, K. Kiyota, N. Licitra, L. Nicolatou-Galitis, O. Pinto, M. Santos, M. Schmalz, C. Sherman, A.C. Tomaszewska, I.M. Verdonck De Leeuw, I. Yarom, N. Zotti, P. Hofmeister, D.

Subjects
social sciences, humanities
Abstract

Background The objective of this study was to pilot test an updated version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC QLQ-H&N60). Methods Patients with head and neck cancer were asked to complete a list of 60 head and neck cancer-specific items comprising the updated EORTC head and neck module and the core questionnaire EORTC QLQ-C30. Debriefing interviews were conducted to identify any irrelevant items and confusing or upsetting wording. Results Interviews were performed with 330 patients from 17 countries, representing different head and neck cancer sites and treatments. Forty-one of the 60 items were retained according to the predefined EORTC criteria for module development, for another 2 items the wording was refined, and 17 items were removed. Conclusion The preliminary EORTC QLQ-H&N43 can now be used in academic research. Psychometrics will be tested in a larger field study. © 2014 Wiley Periodicals, Inc. Head Neck 37: 1358-1367, 2015 © 2014 Wiley Periodicals, Inc.

Published
2015

176. Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) : subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1)

Author

Tahara, M., Cohen, E. E. W., Haddad, R. I., Fayette, J., Licitra, L. F., Clement, P. M., Vermorken, J. B., Gauler, Thomas, Cupissol, D., Grau, J. J., Guigay, J., del Campo, J. M., Okami, K., Takahashi, S., Burtness, B., Cong, X. J., Gibson, N., Solca, F., Ehrnrooth, E., and Machiels, J. P. H.

Subjects
Medizin
Published
2015

177. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative

Author

Bogaerts, J., Sydes, M.R., Keat, N., McConnell, A., Benson, A., Ho, A., Roth, A., Fortpied, C., Eng, C., Peckitt, C., Coens, C., Pettaway, C., Arnold, D., Hall, E., Marshall, E., Sclafani, F., Hatcher, H., Earl, H., Ray-Coquard, I., Paul, J., Blay, J.Y., Whelan, J., Panageas, K., Wheatley, K., Harrington, K., Licitra, L., Billingham, L., Hensley, M., McCabe, M., Patel, P.M., Carvajal, R., Wilson, R., Glynne-Jones, R., McWilliams, R., Leyvraz, S., Rao, S., Nicholson, S., Filiaci, V., Negrouk, A., Lacombe, D., Dupont, E., Pauporté, I., Welch, J.J., Law, K., Trimble, T., and Seymour, M.

Abstract

BACKGROUND: The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers and the most important contributor has been research. Progress in rare cancers has been slower, not least because of the challenges of undertaking research. SETTINGS: The International Rare Cancers Initiative (IRCI) is a partnership which aims to stimulate and facilitate the development of international clinical trials for patients with rare cancers. It is focused on interventional--usually randomized--clinical trials with the clear goal of improving outcomes for patients. The key challenges are organisational and methodological. A multi-disciplinary workshop to review the methods used in ICRI portfolio trials was held in Amsterdam in September 2013. Other as-yet unrealised methods were also discussed. RESULTS: The IRCI trials are each presented to exemplify possible approaches to designing credible trials in rare cancers. Researchers may consider these for use in future trials and understand the choices made for each design. INTERPRETATION: Trials can be designed using a wide array of possibilities. There is no 'one size fits all' solution. In order to make progress in the rare diseases, decisions to change practice will have to be based on less direct evidence from clinical trials than in more common diseases.

Published
2015

178. Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III

Author

Singer, S., Araujo, C., Arraras, J.I., Baumann, I, Boehm, A., Herlofson, B.B., Silva, J.C., Chie, W.C., Fisher, S., Guntinas-Lichius, O., Hammerlid, E., Irarrazaval, M.E., Hjermstad, M.J., Jensen, K., Kiyota, N., Licitra, L., Nicolatou-Galitis, O., Pinto, M., Santos, M., Schmalz, C., Sherman, A.C., Tomaszewska, I.M., de Leeuw, I.M., Yarom, N., Zotti, P., Hofmeister, D., Clinical Psychology, EMGO+ - Mental Health, Otolaryngology / Head & Neck Surgery, EMGO - Mental health, and CCA - Quality of life

Subjects
Male, Pilot Projects, Risk Assessment, Sex Factors, SDG 17 - Partnerships for the Goals, SDG 3 - Good Health and Well-being, Sickness Impact Profile, Surveys and Questionnaires, Adaptation, Psychological, Health Status Indicators, Humans, Societies, Medical, Aged, Age Factors, social sciences, Middle Aged, Combined Modality Therapy, humanities, Europe, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Quality of Life, Female, Stress, Psychological
Abstract

Background The objective of this study was to pilot test an updated version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC QLQ-H&N60). Methods Patients with head and neck cancer were asked to complete a list of 60 head and neck cancer-specific items comprising the updated EORTC head and neck module and the core questionnaire EORTC QLQ-C30. Debriefing interviews were conducted to identify any irrelevant items and confusing or upsetting wording. Results Interviews were performed with 330 patients from 17 countries, representing different head and neck cancer sites and treatments. Forty-one of the 60 items were retained according to the predefined EORTC criteria for module development, for another 2 items the wording was refined, and 17 items were removed. Conclusion The preliminary EORTC QLQ-H&N43 can now be used in academic research. Psychometrics will be tested in a larger field study.

Published
2015

180. Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study

Author

Singer, S., Husson, O., Tomaszewska, I.M., Locati, L.D., Kiyota, N., Scheidemann-Wesp, U., Hofmeister, D., Winterbotham, M., Brannan, C., Araujo, C., Gamper, E.M., Kulis, D., Rimmele, H., Andry, G., Licitra, L., Singer, S., Husson, O., Tomaszewska, I.M., Locati, L.D., Kiyota, N., Scheidemann-Wesp, U., Hofmeister, D., Winterbotham, M., Brannan, C., Araujo, C., Gamper, E.M., Kulis, D., Rimmele, H., Andry, G., and Licitra, L.

Abstract

Item does not contain fulltext, BACKGROUND: The objectives of this study were to determine quality of life (QoL) issues that are relevant to thyroid cancer patients cross-culturally, and to identify those with highest relevance to them in addition to the more general issues covered by the core European Organisation for Research and Treatment of Cancer QoL questionnaire (EORTC QLQ-C30). METHODS: A systematic literature search provided a list of potentially relevant QoL issues to supplement the core questionnaire EORTC QLQ-C30, which is widely used in research and in care and addresses QoL issues relevant to all groups of cancer patients. A panel of experts revised this list, and thyroid cancer patients rated the issues regarding their relevance for QoL by selecting the 25 issues that they would include in a thyroid cancer-specific QoL module. RESULTS: The literature search and expert discussion provided a list of 71 QoL issues that was rated by thyroid cancer patients (n = 110) from seven countries. All issues were of high priority to at least some of the patients. The most frequently selected issues were sudden attacks of tiredness, exhaustion, quality of sleep, employment, social support, fear of cancer progression, fear of second operation, difficulties swallowing, and globus sensation. CONCLUSIONS: Thyroid cancer patients cross-culturally rate fatigue-related issues as highly important for their QoL, calling for increased efforts to find successful treatments for this problem. Vocational rehabilitation is also highly relevant for them and should therefore be an important aim of multidisciplinary care. The third important area of concern is psychological issues, especially fear of progression and of additional treatments.

Published
2016

181. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, Clement, P M, Gauler, T, Machiels, Jean-Pascal, Haddad, R I, Fayette, J, Licitra, L F, Tahara, M, Cohen, E E W, Cupissol, D, Grau, J J, Guigay, J, Caponigro, F, de Castro, G, de Souza Viana, L, Keilholz, U, Del Campo, J M, Cong, X J, Ehrnrooth, E, Vermorken, J B, LUX-H&N 1 investigators, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, Clement, P M, Gauler, T, Machiels, Jean-Pascal, Haddad, R I, Fayette, J, Licitra, L F, Tahara, M, Cohen, E E W, Cupissol, D, Grau, J J, Guigay, J, Caponigro, F, de Castro, G, de Souza Viana, L, Keilholz, U, Del Campo, J M, Cong, X J, Ehrnrooth, E, Vermorken, J B, and LUX-H&N 1 investigators

Abstract

BACKGROUND: In the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients progressing on/after platinum-based therapy. This report evaluates afatinib efficacy and safety in prespecified subgroups of patients aged ≥65 and <65 years. PATIENTS AND METHODS: Patients were randomized (2:1) to 40 mg/day oral afatinib or 40 mg/m(2)/week intravenous methotrexate. PFS was the primary end point; overall survival (OS) was the key secondary end point. Other end points included: objective response rate (ORR), patient-reported outcomes, tumor shrinkage, and safety. Disease control rate (DCR) was also assessed. RESULTS: Of 483 randomized patients, 27% (83 afatinib; 45 methotrexate) were aged ≥65 years (older) and 73% (239 afatinib; 116 methotrexate) <65 years (younger) at study entry. Similar PFS benefit with afatinib versus methotrexate was observed in older {median 2.8 versus 2.3 months, hazard ratio (HR) = 0.68 [95% confidence interval (CI) 0.45-1.03], P = 0.061} and younger patients [2.6 versus 1.6 months, HR = 0.79 (0.62-1.01), P = 0.052]. In older and younger patients, the median OS with afatinib versus methotrexate was 7.3 versus 6.4 months [HR = 0.84 (0.54-1.31)] and 6.7 versus 6.2 months [HR = 0.98 (0.76-1.28)]. ORRs with afatinib versus methotrexate were 10.8% versus 6.7% and 10.0% versus 5.2%; DCRs were 53.0% versus 37.8% and 47.7% versus 38.8% in older and younger patients, respectively. In both subgroups, the most frequent treatment-related adverse events were rash/acne (73%-77%) and diarrhea (70%-80%) with afatinib, and stomatitis (43%) and fatigue (31%-34%) with methotrexate. Fewer treatment-related discontinuations were observed with afatinib (each subgroup 7% versus 16%). A trend toward improved time to deterioration of global health status, pain, and swallowing with afatinib was observed in both subgroup

Published
2016

182. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

Author

Vermorken, J. B. Psyrri, A. Mesia, R. Peyrade, F. Beier, F. de Blas, B. Celik, I. Licitra, L.

Subjects
virus diseases, female genital diseases and pregnancy complications
Abstract

Adding cetuximab to chemotherapy improved survival in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Although HPV and p16 statuses have prognostic value, the observed survival benefit conferred by cetuximab is independent of both. This pattern remained in a combined analysis of both p16 and HPV and in patients with oropharyngeal cancer separately.Tumor human papillomavirus (HPV) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Prognostic value in recurrent and/or metastatic (R/M) disease remains to be confirmed. This retrospective analysis of the EXTREME trial, comparing chemotherapy plus cetuximab with chemotherapy first line in R/M SCCHN, investigated efficacy and prognosis according to tumor p16 and HPV status. Paired tissue samples were used: p16INK4A expression was assessed by immunohistochemistry, and HPV status determined in extracted DNA samples using oligonucleotide hybridization assays. Altogether, 416 of 442 patients had tumor samples available for p16 and HPV: 10% of tumors were p16 positive and 5% were HPV positive. Adding cetuximab to chemotherapy improved survival, irrespective of tumor p16 or HPV status. This pattern remained in a combined analysis of p16 and HPV. p16 positivity and HPV positivity were associated with prolonged survival compared with p16 negativity and HPV negativity. Subgroup analysis of patients with oropharyngeal cancer demonstrated a similar pattern to all evaluable patients. The results from this analysis suggest that p16 and HPV status have prognostic value in R/M SCCHN and survival benefits of chemotherapy plus cetuximab over chemotherapy alone are independent of tumor p16 and HPV status.

Published
2014

183. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project

Author

Stiller, C. A, Trama, A., Brewster, D. H., Verne, J., Bouchardy, C., Navarro, C., Chirlaque, M. D., Marcos Gragera, R., Visser, O., Serraino, D., Weiderpass, E., Dei Tos, A. P., Ascoli, V., Zielonk, N., Van Eycken, E., Sundseth, H., Hedelin, G., Bouvier, A. M., Woronoff, A. S., Buemi, A., Tretarre, B., Colonna, M., Bara, S., Ganry, O., Grosclaude, P., Baconnier, S., Holleczek, B., Geissler, J., Wartenberg, M., Tryggvadottir, L., Deady, S., Bellu, F., Ferretti, Stefano, Vercelli, M., Vitarelli, S., Federico, M., Fusco, M., Michiara, M., Giacomin, A., Tumino, R., Mangone, L., Falcini, F., Senatore, G., Budroni, M., Piffer, S., Crocetti, E., La Rosa, F., Tagliabue, G., Zambon, P., Gatta, G., Gronchi, A., Licitra, L., Ruzza, M., Sowe, S., Capocaccia, R., De Angelis, R., Mallone, S., Tavilla, A., England, K., Ursin, G., Rachtan, J., Gozdz, S., Zwierko, M., Bielska Lasota, M., Slowinski, J., Miranda, A., Safaei Diba, C., Primic Zakelj, M., Mateos, A., Bidaurrazaga, J., Torrella Ramos, A., Ardanaz, E., Galceran, J., Martinez Garcia, C., Sanchez Perez, M. J., Melchor, J. M., Adolfsson, J., Lambe, M., Möller, T. R., Ringborg, U., Jundt, G., Usel, M., Ess, S. M., Spitale, A., Konzelmann, I., Lutz, J. M., Coebergh, J. W. W., Otter, R., Siesling, S., van der Zwan, J. M., Schouten, H., Greenberg, D. C., Wilkinson, J., Roche, M., Meechan, D., Lawrence, G., Mackay, J., Gavin, A., Kunkler, I., and White, C.

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, Cancer Research, Survival, Epidemiology, Population, Socio-culturale, Kaposi, Bone Sarcoma, Acquired immunodeficiency syndrome (AIDS), medicine, Prevalence, Humans, Rare cancers, education, Sarcoma, Kaposi, ddc:613, Aged, Population-based study, education.field_of_study, Europe, Incidence, Kaposi sarcoma, Female, Middle Aged, Survival Analysis, Oncology, Medicine (all), Classic Kaposi Sarcoma, Relative survival, business.industry, Incidence (epidemiology), Cancer, Sarcoma, medicine.disease, Surgery, business
Abstract

Kaposi sarcoma (KS) is a virus-related malignancy which most frequently arises in skin, though visceral sites can also be involved. Infection with Kaposi sarcoma herpes virus (KSHV or HHV-8) is required for development of KS. Nowadays, most cases worldwide occur in persons who are immunosuppressed, usually because of HIV infection or as a result of therapy to combat rejection of a transplanted organ, but classic Kaposi sarcoma is predominantly a disease of the elderly without apparent immunosuppression. We analyzed 2667 KS incident cases diagnosed during 1995-2002 and registered by 75 population-based European cancer registries contributing to the RARECARE project. Total crude and age-standardized incidence rate was 0.3 per 100,000 per year with an estimated 1642 new cases per year in the EU27 countries. Age-standardized incidence rate was 0.8 per 100,000 in Southern Europe but below 0.3 per 100,000 in all other regions. The elevated rate in southern Europe was attributable to a combination of classic Kaposi sarcoma in some Mediterranean countries and the relatively high incidence of AIDS in several countries. Five-year relative survival for 2000-2002 by the period method was 75%. More than 10,000 persons were estimated to be alive in Europe at the beginning of 2008 with a past diagnosis of KS. The aetiological link with suppressed immunity means that many people alive following diagnosis of KS suffer comorbidity from a pre-existing condition. While KS is a rare cancer, it has a relatively good prognosis and so the number of people affected by it is quite large. Thus it provides a notable example of the importance of networking in diagnosis, therapy and research for rare cancers.

Published
2014

185. Preliminary Plan for the recovery of the asphalt mines of the Irminio Valley

Author

CASSARINO G. S, CORALLO E, GRECO V, LAQUIDARA I, LICITRA L, LO GIOCO S, OCCHIPINTI R, RABANTE M., Dipasquale, Mario, and CASSARINO G S, CORALLO E, DIPASQUALE M, GRECO V, LAQUIDARA I, LICITRA L, LO GIOCO S, OCCHIPINTI R, RABANTE M

Subjects
RECUPERO MINERARIO, MASTERPLAN, MINIERE DI ASFALTO, Settore GEO/05 - Geologia Applicata
Published
2008

187. Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer: a single center experience

Author

Granata, R., primary, Bossi, P., additional, Bergamini, C., additional, Alfieri, S., additional, Resteghini, C., additional, Galbiati, D., additional, Orlandi, E., additional, Iacovelli, N.A., additional, Fallai, C., additional, Guzzo, M., additional, Infante, G., additional, Locati, L., additional, Miceli, R., additional, Mariani, L., additional, and Licitra, L., additional

Published
2016
Full Text
View/download PDF

189. Individual patient data meta-analysis of the impact of treatment expertise on the outcome of head and neck cancer patients treated within 6 randomized trials

Author

Bossi, P., primary, Miceli, R., additional, Benasso, M., additional, Corvò, R., additional, Bacigalupo, A., additional, Sanguineti, G., additional, Fallai, C., additional, Merlano, M.C., additional, Infante, G., additional, Dani, C., additional, Di Giannantonio, V., additional, and Licitra, L., additional

Published
2016
Full Text
View/download PDF

190. An added value to Multidisciplinary Team: does a Tutor help to manage head and neck cancer patients?

Author

Cassini, P., primary, Alfieri, S., additional, Bossi, P., additional, Bergamini, C., additional, Granata, R., additional, Resteghini, C., additional, Galbiati, D., additional, Iacovelli, N.A., additional, Orlandi, E., additional, Favales, F., additional, Villa, C., additional, Pistillo, P., additional, Locati, L., additional, and Licitra, L., additional

Published
2016
Full Text
View/download PDF

191. Long-term update of the 24954 EORTC phase III trial on larynx preservation

Author

Henriques De Figueiredo, B., primary, Fortpied, C., additional, Menis, J., additional, Lefebvre, J.L., additional, Barzan, L., additional, de Raucourt, D., additional, Geoffrois, L., additional, Giurgea, L., additional, Hupperets, P., additional, Leemans, C.R., additional, Licitra, L., additional, Rolland, F., additional, Tesselaar, M., additional, Vermorken, J.B., additional, and Grégoire, V., additional

Published
2016
Full Text
View/download PDF

193. Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients

Author

Villa, C., primary, Meregaglia, M., additional, Rognogni, C., additional, Pistillo, P., additional, Orlandi, E., additional, Iacovelli, A., additional, Granata, R., additional, Alfieri, S., additional, Bergamini, C., additional, Resteghini, C., additional, Locati, L., additional, Bossi, P., additional, Guzzo, M., additional, Licitra, L., additional, and Favales, F., additional

Published
2016
Full Text
View/download PDF

194. RANK expression in EBV associated nasopharyngeal cancer metastasis in non-endemic setting: a possible immunologic pathway to be targeted?

Author

Resteghini, C., primary, Alfieri, S., additional, Quattrone, P., additional, Dominoni, F., additional, Garzone, G., additional, Orlandi, E., additional, Locati, L., additional, Bergamini, C., additional, Galbiati, D., additional, Iacovelli, N.A., additional, Licitra, L., additional, and Bossi, P., additional

Published
2016
Full Text
View/download PDF

199. EP-1080: Definitive or adjuvant IMRT for locally advanced sinonasal tumors: outcome and prognostic factors

Author

Orlandi, E., primary, Cavallo, A., additional, De Ponti, E., additional, Iacovelli, N.A., additional, Bossi, P., additional, Nicolai, P., additional, Castelnuovo, P., additional, Guzzo, M., additional, Calareso, G., additional, Naimo, S., additional, Bergamini, C., additional, Locati, L., additional, Licitra, L., additional, Pignoli, E., additional, and Fallai, C., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results